Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 91 - 100 of 1165

Wynzora (calcipotriol)

Status:

Under consideration for negotiation

Manufacturer:

Knight Therapeutics Inc.

Indication:

For the treatment of plaque psoriasis after the failure of a vitamin D analogue or a medium- or high-potency topical corticosteroid

Last updated July 21, 2026

Tezspire (tezepelumab)

Status:

Active negotiation

Manufacturer:

AstraZeneca Canada Inc.

Indication:

As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery

Last updated July 21, 2026

Epysqli (eculizumab)

Status:

Active negotiation

Manufacturer:

Samsung Bioepis Co., Ltd.

Indication:

Multiple Indications

Last updated July 16, 2026

Saphnelo (anifrolumab)

Status:

Under consideration for negotiation

Manufacturer:

AstraZeneca Canada Inc.

Indication:

In addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus

Last updated July 13, 2026

Imfinzi (durvalumab)

Status:

Negotiations were not pursued

Manufacturer:

AstraZeneca Canada Inc.

Indication:

In combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy after surgery, is indicated for the treatment of resectable stage II, IIIA, or IIIB (T3-4 N2) non–small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

Last updated July 13, 2026

Vyvgart (efgartigimod alfa)

Status:

Active negotiation

Manufacturer:

Argenx Canada Inc.

Indication:

Chronic inflammatory demyelinating polyneuropathy

Last updated July 13, 2026

Pombiliti with Opfolda (cipaglucosidase alfa with miglustat)

Status:

Concluded with an LOI

Manufacturer:

Amicus Therapeutics Canada Inc.

Indication:

Pompe disease

Last updated July 8, 2026

Bomyntra (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Fresenius Kabi Canada Ltd.

Indication:

Reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity; and treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate

Last updated July 7, 2026

Conexxence (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Fresenius Kabi Canada Ltd.

Indication:

Treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture; treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture

Last updated July 7, 2026

Movantik (naloxegol)

Status:

Concluded with an LOI

Manufacturer:

Knight Therapeutics Inc.

Indication:

Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).

Last updated July 7, 2026

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 8
  • Page 9
  • Current page 10
  • Page 11
  • Page 12
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use